

# CITATION REPORT

List of articles citing

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

DOI: 10.1016/s0140-6736(10)60888-4  
Lancet, The, 2010, 376, 595-605.

**Source:** <https://exaly.com/paper-pdf/49636821/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
681	New developments in the treatment and prevention of vascular disease--part 1. <b>2010</b> , 16, 3767-9		1
680	Lifestyle modification in the management of the metabolic syndrome: achievements and challenges. <b>2010</b> , Volume 3, 373-385		38
679	Naltrexone combined with bupropion shows promise for weight loss. <b>2010</b> , 7, 533-533		
678	Well-being of obese individuals: therapeutic perspectives. <b>2010</b> , 2, 1729-33		2
677	Is cardiometabolic risk improved by weight-loss drugs?. <i>Lancet, The</i> , <b>2010</b> , 376, 567-8	40	11
676	Combination therapy with naltrexone and bupropion for obesity. <i>Expert Opinion on Pharmacotherapy</i> , <b>2011</b> , 12, 1813-26	4	22
675	Medical therapy for obesity. <b>2011</b> , 21, 203-12		1
674	Binge eating disorder and the outcome of bariatric surgery at one year: a prospective, observational study. <b>2011</b> , 19, 1220-8		82
673	[Paediatric obesities: from childhood to adolescence]. <b>2011</b> , 75, 63.e1-23		12
672	Drug treatment of obesity. <b>2011</b> , 34, 871-80		8
671	Obesity in 2010: the future of obesity medicine: where do we go from here?. <b>2011</b> , 7, 69-70		8
670	New drug targets for the treatment of obesity. <b>2011</b> , 90, 40-51		94
669	Endogenous opiates and behavior: 2010. <b>2011</b> , 32, 2522-52		41
668	Lorcaserin: an investigational serotonin 2C agonist for weight loss. <b>2011</b> , 68, 2029-37		30
667	Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , <b>2011</b> , 377, 1341-52	40	611
666	Combination treatment to CONQUER obesity?. <i>Lancet, The</i> , <b>2011</b> , 377, 1295-7	40	8
665	Aspectos do acompanhamento psiquiátrico de pacientes obesos sob tratamento bariátrico: revisão. <b>2011</b> , 38, 148-154		9

664 Bibliography. 275-330

663 . 2011, 23

662 Predictors of weight loss and maintenance in patients treated with antiobesity drugs. **2011**, 4, 229-43 11

661 Pharmacological treatment of obesity in children and adolescents: present and future. **2011**, 2011, 928165 13

660 Where now for obesity research?. **2011**, 1, 475-477 1

659 Endogenous Peptides and Their Receptors as Drug Discovery Targets for the Treatment of Metabolic Disease. **2011**, 245-268

658 Pharmacotherapy for obesity: a field in crisis?. **2011**, 6, 563-577 4

657 Review article: the role of gastric motility in the control of food intake. **2011**, 33, 880-94 201

656 Regulation of body weight: what is the regulated parameter?. **2011**, 104, 599-607 17

655 [Psychotropic drugs and diabetes]. **2011**, 161, 531-42 0

654 Treatment of non-alcoholic fatty liver disease with focus on emerging drugs. **2011**, 16, 121-36 15

653 Comparative efficiency and safety of pharmacological approaches to the management of obesity. **2011**, 34 Suppl 2, S349-54 8

652 Naltrexone/bupropion: an investigational combination for weight loss and maintenance. **2011**, 4, 489-94 15

651 Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block?'. **2011**, 43, 249-58 19

650 Activation of  $\mu$ -opioid receptors in the dorsal striatum is necessary for adult social attachment in monogamous prairie voles. **2011**, 36, 2200-10 94

649 Role of behavioral medicine in primary care. **2012**, 25, 121-7 5

648 Current world literature. **2012**, 25, 155-62

647 Pharmacotherapeutic Options for the Treatment of Patients with Obesity. **2012**, 28, 211-218

646	Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. <b>2012</b> , 36, 843-54	408
645	Filling the treatment gap in the weight management of overweight and obese patients. <b>2012</b> , 2, S39-S42	3
644	Medical therapy for the patient with obesity. <b>2012</b> , 125, 1695-703	83
643	Recent advancements in drug treatment of obesity. <b>2012</b> , 12, 456-60	37
642	Association of Adolescent Obesity With Risk of Severe Obesity in Adulthood. <b>2012</b> , 2012, 442-444	
641	Clinical assessment and management of adult obesity. <b>2012</b> , 126, 2870-7	56
640	Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. <b>2012</b> , 172, 1557-64	48
639	Psychopharmacologic treatment of obesity and eating disorders in children and adolescents. <b>2012</b> , 21, 831-59	8
638	Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). <b>2012</b> , 20, 330-42	393
637	Do we need anti-obesity drugs?. <b>2012</b> , 28 Suppl 2, 8-20	24
636	Animal models to explore the effects of CNS drugs on food intake and energy expenditure. <b>2012</b> , 63, 124-31	10
635	The link between stress and feeding behaviour. <b>2012</b> , 63, 97-110	162
634	Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons. <b>2012</b> , 11, 675-91	148
633	The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction. <b>2012</b> , 224, 1-26	197
632	Gut hormones: the future of obesity treatment?. <b>2012</b> , 74, 911-9	17
631	Current pharmacotherapy options for bulimia nervosa and binge eating disorder. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 2015-26	4 29
630	Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications. <b>2012</b> , 35, 4-16	113
629	Anti-Obesity Drugs: A Review about Their Effects and Safety. <b>2012</b> , 36, 13-25	357

628	Clinical review: Regulation of food intake, energy balance, and body fat mass: implications for the pathogenesis and treatment of obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, 745-55 <sup>5,6</sup>	176
627	Obesity and the Cardiorenal Metabolic Syndrome: Therapeutic Modalities and Their Efficacy in Improving Cardiovascular and Renal Risk Factors. <b>2012</b> , 2, 314-327	17
626	Sleep Loss and Obesity. <b>2012</b> ,	3
625	Drug treatment of obesity in cardiovascular disease. <b>2012</b> , 12, 93-104	12
624	Pharmacological management of binge eating disorder: current and emerging treatment options. <b>2012</b> , 8, 219-41	49
623	Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity. <b>2012</b> , 6, 10-20	207
622	Pharmacologic management of obesity. <b>2012</b> , 58, 140-3	5
621	Pharmacological Treatment of Obesity. <b>2012</b> , 203-225	2
620	Reuptake inhibitors of dopamine, noradrenaline, and serotonin. <b>2012</b> , 339-47	16
619	Recent advances in the pathophysiology and pharmacological treatment of obesity. <b>2012</b> , 37, 525-35	22
618	Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults. <b>2012</b> , 14, 335-40	34
617	Advances in medical therapy for weight loss and the weight-centric management of type 2 diabetes mellitus. <b>2012</b> , 14, 60-9	20
616	The impact of weight loss among seniors on Medicare spending. <b>2013</b> , 3, 7	12
615	Acute behavioural effects of bupropion and naltrexone, alone and in combination, in non-deprived male rats presented with palatable mash. <b>2013</b> , 228, 291-307	21
614	The unrelenting fall of the pharmacological treatment of obesity. <b>2013</b> , 44, 598-609	18
613	Pharmacologic treatment options for obesity: what is old is new again. <b>2013</b> , 15, 182-9	26
612	Bupropion induced changes in exploratory and anxiety-like behaviour in NMRI male mice depends on the age. <b>2013</b> , 98, 117-24	7
611	Strategies for preventing type 2 diabetes: an update for clinicians. <b>2013</b> , 4, 242-61	34

610	Mechanisms underlying current and future anti-obesity drugs. <b>2013</b> , 36, 133-40	83
609	New options for the treatment of obesity and type 2 diabetes mellitus (narrative review). <b>2013</b> , 27, 508-18	34
608	Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. <b>2013</b> , 36, 4022-9	262
607	Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association. <b>2013</b> , 7, 304-83	241
606	Fixed-dose combination of phentermine-topiramate for the treatment of obesity. <b>2013</b> , 6, 235-41	8
605	A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). <b>2013</b> , 21, 935-43	381
604	Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity. <b>2013</b> , 15, 863-6	36
603	Pharmacotherapy for childhood obesity: present and future prospects. <b>2013</b> , 37, 1-15	45
602	Weight Loss in the Management of Obstructive Sleep Apnea. <b>2013</b> , 8, 517-525	
601	Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models. <b>2013</b> , 698, 292-8	22
600	[Pharmacological treatment of obesity]. <b>2013</b> , 60 Suppl 1, 19-22	
599	Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of The Obesity Society and the American Society of Hypertension. <b>2013</b> , 15, 14-33	251
598	Update on treatment strategies for obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, 1299-306	5.6 49
597	New pharmacological approaches for obesity management. <b>2013</b> , 9, 467-78	42
596	Hypothalamic $\mu$ opioid receptor modulates the orexigenic effect of ghrelin. <b>2013</b> , 38, 1296-307	27
595	Reducing the risk of obesity: defining the role of weight loss drugs. <b>2013</b> , 33, 1308-21	11
594	Why do we need drugs to treat the patient with obesity?. <b>2013</b> , 21, 893-9	30
593	Can neuropeptides treat obesity? A review of neuropeptides and their potential role in the treatment of obesity. <b>2013</b> , 170, 1333-48	24

592	Pharmacotherapy of obesity: clinical treatments and considerations. <b>2013</b> , 345, 284-288	98
591	Weight considerations in psychotropic drug prescribing and switching. <b>2013</b> , 125, 117-29	60
590	New medications for obesity management: changing the landscape of obesity treatment. <b>2013</b> , 20, 407-11	10
589	A complications-based clinical staging of obesity to guide treatment modality and intensity. <b>2013</b> , 20, 377-88	42
588	Zonisamide for weight reduction in obese adults. <b>2013</b> , 310, 637-8	4
587	Severe obesity in children and adolescents: identification, associated health risks, and treatment approaches: a scientific statement from the American Heart Association. <b>2013</b> , 128, 1689-712	640
586	Obesity consults--comprehensive obesity management in 2013: understanding the shifting paradigm. <b>2013</b> , 21 Suppl 2, S3-13; quiz S14-5	4
585	Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment--a position paper of the The Obesity Society and The American Society of Hypertension. <b>2013</b> , 21, 8-24	155
584	A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder. <b>2013</b> , 46, 239-45	34
583	Obesity pharmacotherapy: current perspectives and future directions. <b>2013</b> , 9, 33-54	12
582	New tools for weight-loss therapy enable a more robust medical model for obesity treatment: rationale for a complications-centric approach. <b>2013</b> , 19, 864-74	51
581	Examination of food reward and energy intake under laboratory and free-living conditions in a trait binge eating subtype of obesity. <b>2013</b> , 4, 757	29
580	Interrupting the natural history of diabetes mellitus: lifestyle, pharmacological and surgical strategies targeting disease progression. <b>2014</b> , 12, 155-67	6
579	Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. <b>2014</b> , 8, 1419-27	123
578	Antiobesity pharmacotherapy for patients with type 2 diabetes: focus on long-term management. <b>2014</b> , 29, 410-7	11
577	Current pharmacotherapy for obesity: extrapolation of clinical trials data to practice. <i>Expert Opinion on Pharmacotherapy</i> , <b>2014</b> , 15, 809-22	4 20
576	Managing the side effects associated with commonly used treatments for bipolar depression. <b>2014</b> , 169 Suppl 1, S34-44	43
575	Treatment of Obesity?. <b>2014</b> ,	

574	Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues. <b>2014</b> , 38, 682-8	116
573	Safety and efficacy of lorcaserin: a combined analysis of the BLOOM and BLOSSOM trials. <b>2014</b> , 126, 7-18	54
572	How Relevant is Food Craving to Obesity and Its Treatment?. <b>2014</b> , 5, 164	56
571	Update on obesity pharmacotherapy. <b>2014</b> , 1311, 1-13	59
570	Gene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomes. <b>2014</b> , 42, 1971-7	19
569	Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit. <b>2014</b> , 37, 693-9	25
568	Weight reduction and maintenance with IQP-PV-101: a 12-week randomized controlled study with a 24-week open label period. <b>2014</b> , 22, 645-51	19
567	IQP-GC-101 reduces body weight and body fat mass: a randomized, double-blind, placebo-controlled study. <b>2014</b> , 28, 1520-6	15
566	Pharmacological means of reducing human drug dependence: a selective and narrative review of the clinical literature. <b>2014</b> , 77, 242-52	13
565	Medical management of obesity: a comprehensive review. <b>2014</b> , 57, 465-84	13
564	Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. <b>2014</b> , 2, 911-22	123
563	New and emerging drug molecules against obesity. <b>2014</b> , 19, 65-76	48
562	Neuroendocrine circuits governing energy balance and stress regulation: functional overlap and therapeutic implications. <b>2014</b> , 19, 910-25	65
561	Bariatric surgery in class I obesity : a Position Statement from the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO). <b>2014</b> , 24, 487-519	71
560	Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. <b>2014</b> , 84, 1-11	89
559	Obesity and liver disease: the epidemic of the twenty-first century. <b>2014</b> , 18, 1-18	81
558	Long-term drug treatment for obesity: a systematic and clinical review. <b>2014</b> , 311, 74-86	535
557	Tolerability and safety of the new anti-obesity medications. <b>2014</b> , 37, 693-702	59



556	Drug safety evaluation of naltrexone/bupropion for the treatment of obesity. <b>2014</b> , 13, 831-41		17
555	Treatment of the Obese Patient. <b>2014</b> ,		1
554	A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. <b>2014</b> , 38, 1097-103		34
553	Medical treatment of obesity: the past, the present and the future. <b>2014</b> , 28, 665-84		58
552	Opposing neural effects of naltrexone on food reward and aversion: implications for the treatment of obesity. <b>2014</b> , 231, 4323-35		36
551	Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents. <b>2014</b> , 39, 475-84		5
550	Searching for synergy in silico, in vitro and in vivo. <b>2014</b> , 1, 30-43		22
549	The efficacy of a low dose combination of topiramate and naltrexone on ethanol reinforcement and consumption in rat models. <b>2014</b> , 116, 107-15		6
548	Combination Therapy: Topiramate and Phentermine. <b>2014</b> , 279-292		
547	Where there is smoke there is sleep apnea: exploring the relationship between smoking and sleep apnea. <b>2014</b> , 146, 1673-1680		48
546	Tools for Successful Weight Management in Primary Care. <b>2015</b> , 350, 485-97		3
545	American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan [2015. <b>2015</b> , 21, 1-87		39 <sup>o</sup>
544	[The Update of Obesity Syndrome: Molecular Mechanism, Pathophysiology and Therapies. Topics: II. Recent Topics on Care and Treatment of the Obesity Syndrome; 3. Pharmacotherapy of obesity]. <b>2015</b> , 104, 735-41		1
543	Evidence that Melanocortin Receptor Agonist Melanotan-II Synergistically Augments the Ability of Naltrexone to Blunt Binge-Like Ethanol Intake in Male C57BL/6J Mice. <b>2015</b> , 39, 1425-33		16
542	Patient-reported quality of life in a randomized placebo-controlled trial of naltrexone/bupropion for obesity. <i>Clinical Obesity</i> , <b>2015</b> , 5, 237-44	3.6	13
541	Obesity medications: what does the future look like?. <b>2015</b> , 22, 360-6		14
54 <sup>o</sup>	Personality, attrition and weight loss in treatment seeking women with obesity. <i>Clinical Obesity</i> , <b>2015</b> , 5, 266-72	3.6	8
539	Letter to the editor: naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. <b>2015</b> , 9, 419-23		

538	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2015 EXECUTIVE SUMMARY. <b>2015</b> , 21, 1403-14	20
537	Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain. <b>2015</b> , 53, 19-22	2
536	The efficacy and safety of the naltrexone/bupropion combination for the treatment of obesity: an update. <b>2015</b> , 14, 370-5	9
535	Recent Advances for Anti-Obesity Agents. <i>Journal of Korean Diabetes</i> , <b>2015</b> , 16, 260	0.1
534	Weight Loss Pharmacotherapy of Obese Non-Diabetic and Type 2 Diabetic Patients. <b>2015</b> , 05,	
533	Obesity: Lifestyle management, bariatric surgery, drugs, and the therapeutic exploitation of gut hormones. <b>2015</b> , 127, 494-502	14
532	Liraglutide: an injectable option for the management of obesity. <b>2015</b> , 49, 938-44	14
531	3 Medical Management of Obesity. <b>2015</b> , 15-38	
530	Liraglutide and obesity: a review of the data so far. <b>2015</b> , 9, 1867-75	63
529	Current and Emerging Pharmacotherapies for Weight Management in Prediabetes and Diabetes. <b>2015</b> , 39 Suppl 5, S134-41	12
528	Obesity Education Strategies for Cancer Prevention in Women's Health. <b>2015</b> , 4, 249-258	5
527	European Guidelines for Obesity Management in Adults. <b>2015</b> , 8, 402-24	509
526	Naltrexone ER/bupropion ER in obesity management: a guide to its use. <b>2015</b> , 31, 417-424	
525	New medications for treatment of obesity: metabolic and cardiovascular effects. <b>2015</b> , 31, 142-52	41
524	Drug treatment of obesity: current status and future prospects. <b>2015</b> , 26, 89-94	68
523	Alcohol preferring (P) rats as a model for examining sex differences in alcohol use disorder and its treatment. <b>2015</b> , 132, 1-9	30
522	A randomised cross-over pilot study investigating the use of acupuncture to promote weight loss and mental health in overweight and obese individuals participating in a weight loss program. <b>2015</b> , 20, 379-87	6
521	Naltrexone ER/Bupropion ER: A Review in Obesity Management. <b>2015</b> , 75, 1269-80	25

520 Naltrexone/bupropion prolonged release. **2015**, 32, 114-115

519 ANTI-OBESITY PHARMACOTHERAPY AND THE POTENTIAL FOR PREVENTING PROGRESSION FROM PREDIABETES TO TYPE 2 DIABETES. **2015**, 21, 634-44 6

518 Recommendations for obesity management and prevention have come a long way. **2015**, 39, 89-90 1

517 Efficacy comparison of medications approved for chronic weight management. **2015**, 23 Suppl 1, S4-7 21

516 Next generation of weight management medications: implications for diabetes and CVD risk. **2015**, 17, 35 13

515 The New Era of Drug Therapy for Obesity: The Evidence and the Expectations. **2015**, 75, 935-45 37

514 Combination phentermine and topiramate extended release in the management of obesity. *Expert Opinion on Pharmacotherapy*, **2015**, 16, 1263-74 4 18

513 The Clinician's Guide to the Treatment of Obesity. **2015**, 2

512 Past and present of antiobesity agents: focus on monoamine modulators. **2015**, 72, 697-706 15

511 Anti-hypertensive drug treatment of patients with and the metabolic syndrome and obesity: a review of evidence, meta-analysis, post hoc and guidelines publications. **2015**, 17, 558 31

510 Naltrexone extended-release plus bupropion extended-release for treatment of obesity. **2015**, 313, 1213-4 41

509 Treatment of obesity: lifestyle and pharmacotherapy. **2015**, 489-504

508 Medications for weight loss. **2015**, 22, 91-7 13

507 Pharmacotherapy of binge-eating disorder: a review. **2015**, 9, 1-19 8

506 ASGE position statement on endoscopic bariatric therapies in clinical practice. **2015**, 82, 767-72 58

505 The 2013 American Heart Association/American College of Cardiology/The Obesity Society Guideline for the Management of Overweight and Obesity in Adults: What Is New About Diet, Drugs, and Surgery for Obesity?. **2015**, 132, 1586-91 17

504 Preliminary validation and principal components analysis of the Control of Eating Questionnaire (CoEQ) for the experience of food craving. **2015**, 69, 1313-7 39

503 Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. **2015**, 132, 691-718 239

502	Revisiting weight reduction and management in the diabetic patient: Novel therapies provide new strategies. <b>2015</b> , 127, 480-93	5
501	Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert Forum. <b>2015</b> , 38, 1567-82	133
500	Pharmacotherapy for the management of obesity. <b>2015</b> , 64, 1376-85	72
499	Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. <b>2015</b> , 38, 1777-803	271
498	Aberrant mesolimbic dopamine-opiate interaction in obesity. <b>2015</b> , 122, 80-6	48
497	Pharmacotherapy for the treatment of obesity. <b>2015</b> , 418 Pt 2, 173-83	23
496	Low levels of physical activity are associated with dysregulation of energy intake and fat mass gain over 1 year. <b>2015</b> , 102, 1332-8	82
495	Multidisciplinary Approach to Obesity. <b>2015</b> ,	6
494	Pharmacological management of obesity in pediatric patients. <b>2015</b> , 49, 220-32	31
493	Pharmacological Management of the Obese Patient. <b>2015</b> , 9, 137-156	
492	Naltrexone HCl/bupropion HCl for chronic weight management in obese adults: patient selection and perspectives. <b>2016</b> , 10, 751-9	16
491	Through Thick and Thin: Identifying Barriers to Bariatric Surgery, Weight Loss Maintenance, and Tailoring Obesity Treatment for the Future. <b>2016</b> , 2016, 8616581	24
490	Counselors Within the Chronic Care Model: Supporting Weight Management. <b>2016</b> , 94, 234-245	0
489	Long-term effects of weight-reducing drugs in people with hypertension. <b>2016</b> , 3, CD007654	31
488	Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles. <b>2016</b> , 18, 558-70	92
487	The substitutability of cigarettes and food: A behavioral economic comparison in normal weight and overweight or obese smokers. <b>2016</b> , 30, 857-867	7
486	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITYEXECUTIVE SUMMARYComplete Guidelines available at <a href="https://www.aace.com/publications/guidelines">https://www.aace.com/publications/guidelines</a> . <b>2016</b> , 22, 842-84	109
485	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY. <b>2016</b> , 22 Suppl 3, 1-203	557

484	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. <b>2016</b> , 22, 84-113		333
483	Management of Obesity. <b>2016</b> , 34, 4295-4305		35
482	2016 Meet-The-Professor: Endocrine Case Management. <b>2016</b> ,		1
481	Pharmacologic Approaches to Weight Management: Recent Gains and Shortfalls in Combating Obesity. <b>2016</b> , 18, 36		9
480	Mood and metabolism: Anhedonia as a clinical target in Type 2 diabetes. <b>2016</b> , 69, 123-32		28
479	Medikamentöse Behandlung der Adipositas. <b>2016</b> , 10, 47-64		0
478	Impulsivity is associated with blood pressure and waist circumference among adolescents with bipolar disorder. <b>2016</b> , 83, 230-239		19
477	Can we win the war on obesity with pharmacotherapy?. <b>2016</b> , 9, 1289-1297		8
476	Acute stimulation of brain mu opioid receptors inhibits glucose-stimulated insulin secretion via sympathetic innervation. <b>2016</b> , 110, 322-332		11
475	The Perioperative Implications of New Weight Loss Drugs. <b>2016</b> , 34, 1-11		0
474	Current drugs for weight loss. <b>2016</b> , 33, 229-232		
473	An update on naltrexone/bupropion extended-release in the treatment of obesity. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 2235-2242	4	6
472	Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome. <b>2016</b> , 18, 76		33
471	Reward-Induced Eating: Therapeutic Approaches to Addressing Food Cravings. <b>2016</b> , 33, 1853-1866		62
470	Naltrexone/Bupropion extended release-induced weight loss is independent of nausea in subjects without diabetes. <i>Clinical Obesity</i> , <b>2016</b> , 6, 305-12	3.6	7
469	Pharmacotherapy for Obesity. <b>2016</b> , 45, 521-38		26
468	Review of pharmacotherapy options for the management of obesity. <b>2016</b> , 28, 107-15		2
467	Characteristics of patients potentially eligible for pharmacotherapy for weight loss in primary care practice in the United States. <b>2016</b> , 2, 104-114		16

466	Weight maintenance: challenges, tools and strategies for primary care physicians. <b>2016</b> , 17, 81-93	49
465	Obesity. <b>2016</b> ,	2
464	Beyond Traditional Management: The Use of Medications in the Treatment of Obesity. <b>2016</b> , 231-260	
463	Pharmacological management of obesity in patients with type 2 diabetes. <b>2016</b> , 11, 415-423	
462	Discovery of New Drugs for Weight Loss and Prevention of Weight Regain. <b>2016</b> , 247-284	
461	Cardiovascular Effects of the New Weight Loss Agents. <b>2016</b> , 68, 849-59	16
460	Pharmacological Interventions against Obesity: Current Status and Future Directions. <b>2016</b> , 32, 347-351	5
459	Obesity and Management of Weight Loss. <b>2016</b> , 375, 1187-9	5
458	Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?. <b>2016</b> , 15, 95	39
457	Food cue reactivity and craving predict eating and weight gain: a meta-analytic review. <b>2016</b> , 17, 159-77	335
456	Pharmacological Approaches in the Treatment and Maintenance of Weight Loss. <b>2016</b> , 39 Suppl 2, S260-7	32
455	PATIENT-CENTERED CARE OF THE PATIENT WITH OBESITY. <b>2016</b> , 22, 1-20	0
454	Management of Type 2 Diabetes in the Setting of Morbid Obesity: How Can Weight Gain Be Prevented or Reversed?. <b>2016</b> , 34, 115-20	2
453	Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder. <b>2016</b> , 10, 236-43	10
452	A clinical perspective of obesity, metabolic syndrome and cardiovascular disease. <b>2016</b> , 5, 2048004016633371	193
451	Pharmacological management of nonalcoholic fatty liver disease. <b>2016</b> , 65, 1183-95	70
450	A new era of addiction treatment amplifies the stigma of disease and treatment for individuals with obesity. <b>2016</b> , 40, 1335-6	0
449	Pharmacotherapy for Obesity and Changes in Eating Behavior: a Patient and Physician's Perspective. <b>2016</b> , 33, 1262-6	3

448	Targeting adipose tissue in the treatment of obesity-associated diabetes. <b>2016</b> , 15, 639-660	369
447	Obesity and diabetes mellitus in the Arab world. <b>2016</b> , 11, 301-309	13
446	Role of Bupropion Plus Naltrexone for the Management of Obesity. <b>2016</b> , 32, 125-132	1
445	Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. <b>2016</b> , 315, 2424-34	402
444	Prevention of type 2 Diabetes Mellitus: Potential of pharmacological agents. <b>2016</b> , 30, 357-71	11
443	The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy. <b>2016</b> , 40, 1369-75	40
442	6. Obesity Management for the Treatment of Type 2 Diabetes. <b>2016</b> , 39 Suppl 1, S47-51	78
441	Pharmacotherapy of Obesity and Metabolic Syndrome. <b>2016</b> , 797-809	
440	Functional neuroimaging in obesity and the potential for development of novel treatments. <b>2016</b> , 4, 695-705	28
439	A Comparison of New Pharmacological Agents for the Treatment of Obesity. <b>2016</b> , 50, 376-88	16
438	Management of obesity. <i>Lancet, The</i> , <b>2016</b> , 387, 1947-56	40 461
437	Pharmacological Management. <b>2016</b> , 45-51	
436	Obesity context of type 2 diabetes and medication perspectives. <b>2016</b> , 13, 91-96	1
435	FDA-Approved Anti-Obesity Drugs in the United States. <b>2016</b> , 129, 879.e1-6	83
434	Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. <b>2016</b> , 315, 990-1004	122
433	Differential effects of bupropion on acquisition and performance of an active avoidance task in male mice. <b>2016</b> , 124, 32-7	3
432	Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes. <b>2016</b> , 12, 129-38	16
431	The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity. <b>2016</b> , 7, 92-107	27

430	Extracellular vesicles: Pharmacological modulators of the peripheral and central signals governing obesity. <b>2016</b> , 157, 65-83		20
429	Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity. <b>2016</b> , 9, 27-34		9
428	Neural systems implicated in obesity as an addictive disorder: from biological to behavioral mechanisms. <b>2016</b> , 223, 329-46		17
427	Current Perspectives on Long-term Obesity Pharmacotherapy. <b>2016</b> , 40, 184-91		15
426	Exploratory Literature Meta-Analysis to Characterize the Relationship Between Early and Longer Term Body Weight Loss for Antiobesity Compounds. <b>2017</b> , 57, 52-63		3
425	Nanogel-based nasal ghrelin vaccine prevents obesity. <b>2017</b> , 10, 1351-1360		32
424	White Paper AGA: POWER - Practice Guide on Obesity and Weight Management, Education, and Resources. <b>2017</b> , 15, 631-649.e10		76
423	Vascular risk in obesity: Facts, misconceptions and the unknown. <b>2017</b> , 14, 2-13		19
422	Aggressive clinical approach to obesity improves metabolic and clinical outcomes and can prevent bariatric surgery: a single center experience. <b>2017</b> , 4, 9		7
421	Practical Use of Pharmacotherapy for Obesity. <b>2017</b> , 152, 1765-1779		44
420	Pediatric Obesity-Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 102, 709-757	5.6	485
419	Prevention, diagnosis, and treatment of obesity. 2016 position statement of the Spanish Society for the Study of Obesity. <b>2017</b> , 64, 15-22		4
418	Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data?. <b>2017</b> , 54, 715-725		13
417	Epidemiology of Obesity and Pharmacologic Treatment Options. <b>2017</b> , 32, 441-462		15
416	Extended calorie restriction suppresses overall and specific food cravings: a systematic review and a meta-analysis. <b>2017</b> , 18, 1122-1135		31
415	Early improvement in food cravings are associated with long-term weight loss success in a large clinical sample. <b>2017</b> , 41, 1232-1236		22
414	Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year. <b>2017</b> , 19, 1276-1288		37
413	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY. <b>2017</b> , 23, 207-238		302



412	Pharmacotherapy for Weight Management in the VHA. <b>2017</b> , 32, 70-73	12
411	Mood Disorders and Severe Obesity: A Case Study. <b>2017</b> , 107-121	
410	Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity. <b>2017</b> , 25, 338-345	22
409	Oxytocin system dysfunction as a common mechanism underlying metabolic syndrome and psychiatric symptoms in schizophrenia and bipolar disorders. <b>2017</b> , 45, 1-10	23
408	7. Obesity Management for the Treatment of Type 2 Diabetes. <b>2017</b> , 40, S57-S63	59
407	Psychiatric Care in Severe Obesity. <b>2017</b> ,	1
406	Inkretinbasierte Medikamente zur Diabetes- und Adipositas therapie. <b>2017</b> , 13, 505-513	
405	Phenotypes of Obesity: How it Impacts Management. <b>2017</b> , 19, 55	11
404	Past, present and future of pharmacotherapy for obesity. <b>2017</b> , 29, 256-264	2
403	Obesity management among patients with type 2 diabetes and prediabetes: a focus on lifestyle modifications and evidence of antiobesity medications. <b>2017</b> , 12, 303-313	3
402	Current and emerging pharmacotherapies for obesity in Australia. <b>2017</b> , 11, 501-521	7
401	Effect of Flibanserin Treatment on Body Weight in Premenopausal and Postmenopausal Women with Hypoactive Sexual Desire Disorder: A Post Hoc Analysis. <b>2017</b> , 26, 1161-1168	6
400	Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study. <b>2017</b> , 34, 2307-2315	32
399	Obesity. <b>2017</b> , 477-498	1
398	Cross-sectional and longitudinal associations between different exercise types and food cravings in free-living healthy young adults. <b>2017</b> , 118, 82-89	13
397	Weight management in adults. <b>2017</b> , 139-259	
396	Past, present and future of pharmacotherapy for obesity. <b>2017</b> , 29, 256-264	
395	Combination therapy for obesity. <b>2017</b> , 31, 1503-1508	20

394	Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval and Early Phase Clinical Development. <b>2017</b> , 31, 399-421	2
393	Pharmacotherapy in the Management of Pediatric Obesity. <b>2017</b> , 17, 55	12
392	The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg. <b>2017</b> , 9, 44	33
391	A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI. <b>2017</b> , 17, 1-28	131
390	Bench to bedside in appetite research: Lost in translation?. <b>2017</b> , 76, 163-173	4
389	Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release. <b>2017</b> , 16, 27-39	24
388	Improving efficacy of the adjustable gastric band: studies of the use of adjuvant approaches in a rodent model. <b>2017</b> , 13, 291-304	1
387	Prevention, diagnosis, and treatment of obesity. 2016 position statement of the Spanish Society for the Study of Obesity. <b>2017</b> , 64 Suppl 1, 15-22	40
386	Effects of lorcaserin on pre-existing valvulopathy: A pooled analysis of phase 3 trials. <b>2017</b> , 25, 39-44	12
385	Review of multimodal therapies for obesity treatment: Including dietary, counseling strategies, and pharmacologic interventions. <b>2017</b> , 19, 12-17	7
384	Obesity: New paradigms, interventions and treatments. <b>2017</b> , 15, 338-343	1
383	The Role of the Melanocortin System in Drug and Alcohol Abuse. <b>2017</b> , 136, 121-150	11
382	10. Medical and surgical management of obesity prior to planned pregnancy. <b>2017</b> ,	
381	8. Konservative Therapie. <b>2017</b> , 191-268	
380	Off-label drugs for weight management. <b>2017</b> , 10, 223-234	27
379	Postoperative Analgesia in Morbid Obesity: An Overview of Multimodal Analgesia and Complimentary Therapies. <b>2017</b> , 171-180	
378	Obesity: A Review of Pathogenesis and Management Strategies in Adult. <b>2017</b> , 5, 35-48	9
377	Suppressed Fat Appetite after Roux-en-Y Gastric Bypass Surgery Associates with Reduced Brain Opioid Receptor Availability in Diet-Induced Obese Male Rats. <b>2016</b> , 10, 620	13

376	Weight loss medications in Canada - a new frontier or a repeat of past mistakes?. <b>2017</b> , 10, 413-417		7
375	Obesity Pharmacotherapy in Patients With Type 2 Diabetes. <b>2017</b> , 30, 250-257		17
374	Position of the Bariatric and Metabolic Surgery Section of the Polish Association for the Study on Obesity on the use of pharmacotherapy to support the treatment of obesity before and after surgery. <b>2017</b> , 1, 1-7		
373	Naltrexone/bupropion for obesity. <b>2017</b> , 55, 126-129		5
372	Medical Management of Obesity. <b>2017</b> , 17, 66		
371	Obesity-Induced Hypertension: New Insights. <b>2017</b> , 23, 4620-4625		7
370	Effect of combined naltrexone and bupropion therapy on the brain's functional connectivity. <b>2018</b> , 42, 1890-1899		8
369	Quality of life, binge eating and sexual function in participants treated for obesity with sustained release naltrexone/bupropion. <b>2018</b> , 4, 141-152		15
368	Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK. <i>Clinical Obesity</i> , <b>2018</b> , 8, 211-225	3.6	6
367	Medically Supervised Weight Loss Programs. <b>2018</b> , 211-223		
366	Rationale for Utilization of Obesity Pharmacotherapy in the Active Duty Population. <b>2018</b> , 183, 45-50		2
365	Safety and tolerability of new-generation anti-obesity medications: a narrative review. <b>2018</b> , 130, 173-182		64
364	Expected benefits and motivation to weight loss in relation to treatment outcomes in group-based cognitive-behavior therapy of obesity. <b>2018</b> , 23, 205-214		6
363	Pharmacotherapy for obesity in individuals with type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 223-231	4	12
362	Updates on obesity pharmacotherapy. <b>2018</b> , 1411, 106-119		38
361	The safety of pharmacologic treatment for pediatric obesity. <b>2018</b> , 17, 379-385		23
360	Benefits and Harms in Pivotal Trials of Oral Centrally Acting Antiobesity Medicines: A Systematic Review and Meta-Analysis. <b>2018</b> , 26, 513-521		3
359	Effect of Lorcaserin Alone and in Combination with Phentermine on Food Cravings After 12-Week Treatment: A Randomized Substudy. <b>2018</b> , 26, 332-339		46

358	Neuropharmacology of compulsive eating. <b>2018</b> , 373,	14
357	Intensive lifestyle modifications with or without liraglutide 3mg vs. sleeve gastrectomy: A three-arm non-randomised, controlled, pilot study. <b>2018</b> , 44, 235-242	15
356	New Therapies in Obesity. <b>2018</b> , 271-279	0
355	Potential psychological & neural mechanisms in binge eating disorder: Implications for treatment. <b>2018</b> , 60, 32-44	33
354	Obesity: Pathophysiology and Management. <b>2018</b> , 71, 69-84	192
353	Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis. <b>2018</b> , 154, 1309-1319.e7	39
352	The Science of Obesity Management: An Endocrine Society Scientific Statement. <b>2018</b> , 39, 79-132	304
351	Current pharmacotherapy for obesity. <b>2018</b> , 14, 12-24	192
350	Psychopharmacological advances in eating disorders. <b>2018</b> , 11, 95-108	49
349	Progress and challenges in anti-obesity pharmacotherapy. <b>2018</b> , 6, 237-248	118
348	Model-Based Approach to Predict Adherence to Protocol During Antiobesity Trials. <b>2018</b> , 58, 240-253	3
347	7. Obesity Management for the Treatment of Type 2 Diabetes:. <b>2018</b> , 41, S65-S72	87
346	The role of craving in emotional and uncontrolled eating. <b>2018</b> , 123, 146-151	23
345	Obesity Pharmacotherapy. <b>2018</b> , 102, 135-148	68
344	Reprint of: Healthy Weight and Obesity Prevention: JACC Health Promotion Series. <b>2018</b> , 72, 3027-3052	20
343	Working toward precision medicine approaches to treat severe obesity in adolescents: report of an NIH workshop. <b>2018</b> , 42, 1834-1844	22
342	GOALS FOR MEDICAL TREATMENT IN OBESITY AND PREDIABETES: IMPROVING OUTCOMES FOR BOTH. <b>2018</b> , 24, 1093-1098	0
341	Executive Summary of the 2018 Joint Consensus Document on Cardiovascular Disease Prevention in Italy. <b>2018</b> , 25, 327-341	12

340	When to Initiate Weight Loss Medications in the NAFLD Population. <b>2018</b> , 6,	7
339	The Role of Weight Management in the Treatment of Adult Obstructive Sleep Apnea. An Official American Thoracic Society Clinical Practice Guideline. <b>2018</b> , 198, e70-e87	78
338	Healthy Weight and Obesity Prevention: JACC Health Promotion Series. <b>2018</b> , 72, 1506-1531	172
337	Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. <b>2018</b> , 320, 1172-1191	173
336	Peptide-based multi-agonists: a new paradigm in metabolic pharmacology. <b>2018</b> , 284, 581-602	22
335	Role of Cannabinoids in Obesity. <b>2018</b> , 19,	40
334	Weight Regain After Bariatric Surgery: Prevalence, Etiology, and Treatment. <b>2018</b> , 7, 329-334	53
333	Why Weight? An Analytic Review of Obesity Management, Diabetes Prevention, and Cardiovascular Risk Reduction. <b>2018</b> , 20, 39	15
332	Naltrexone and Bupropion Combination Treatment for Smoking Cessation and Weight Loss in Patients With Schizophrenia. <b>2018</b> , 9, 181	9
331	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY. <b>2018</b> , 24, 91-120	321
330	Centrally Acting Agents for Obesity: Past, Present, and Future. <b>2018</b> , 78, 1113-1132	52
329	Pharmacological interventions for obesity: current and future targets. <b>2018</b> , 5, 202-211	8
328	Konservative Therapie der Adipositas. <b>2018</b> , 22, 106-111	2
327	Medications that cause weight gain and alternatives in Canada: a narrative review. <b>2018</b> , 11, 427-438	29
326	Bupropion and naltrexone combination alters high fructose corn syrup self-administration and gene expression in rats. <b>2018</b> , 135, 547-554	8
325	ASMBS updated position statement on bariatric surgery in class I obesity (BMI 30-35 kg/m). <b>2018</b> , 14, 1071-1087	44
324	Weight Loss Strategies for Treatment of Obesity: Lifestyle Management and Pharmacotherapy. <b>2018</b> , 61, 246-252	38
323	Treatment: New Drugs. <b>2019</b> , 464-472	

322	Precision medicine in adult and pediatric obesity: a clinical perspective. <b>2019</b> , 10, 2042018819863022		12
321	Understanding the Mechanism of Action and Clinical Implications of Anti-Obesity Drugs Recently Approved in Korea. <b>2019</b> , 40, 63-71		4
320	THE BENEFIT OF SHORT-TERM WEIGHT LOSS WITH ANTI-OBESITY MEDICATIONS IN REAL-WORLD CLINICAL PRACTICE. <b>2019</b> , 25, 1022-1028		4
319	Safety and Efficacy of Weight-Loss Pharmacotherapy in Persons Living with HIV: A Review of the Literature and Potential Drug-Drug Interactions with Antiretroviral Therapy. <b>2019</b> , 39, 1204-1215		4
318	Farmacoterapia dell'obesità <i>L Endocrinologo</i> , <b>2019</b> , 20, 374-376	o	
317	Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia. <b>2019</b> , 18, 1149-1160	23	
316	Pharmacotherapeutic strategies for treating binge eating disorder. Evidence from clinical trials and implications for clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 679-690	4	12
315	Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis. <b>2019</b> , 43, 2085-2094		8
314	Incremental cost-effectiveness of evidence-based non-surgical weight loss strategies. <i>Clinical Obesity</i> , <b>2019</b> , 9, e12294	3.6	13
313	Identification and Management of Cardiometabolic Risk after Spinal Cord Injury. <b>2019</b> , 42, 643-677		25
312	Pharmaceutical approaches to weight management: behavioural mechanisms of action. <b>2019</b> , 12, 26-32		1
311	Current treatments for obesity. <b>2019</b> , 19, 205-212		34
310	Obesity an overview: Genetic conditions and recent developments in therapeutic interventions. <b>2019</b> , 13, 2112-2120		7
309	Stereoselective synthesis of novel functionalized cyclohexanone derivatives via the condensation of aromatic aldehydes with acetoacetamide and the influence of the ortho-effect and autocondensation. <b>2019</b> , 60, 1592-1596		9
308	Update on drug safety evaluation of naltrexone/bupropion for the treatment of obesity. <b>2019</b> , 18, 549-552		5
307	Sex differences in the effect of bupropion and naltrexone combination on alcohol drinking in mice. <b>2019</b> , 181, 28-36		8
306	Incorporating Weight Loss Medications Into Hepatology Practice for Nonalcoholic Steatohepatitis. <b>2019</b> , 70, 1443-1456		8
305	Interpreting Ketamine's Opioid Receptor Dependent Effect: Response to Sanacora. <b>2019</b> , 176, 249-250		4

304	Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism: Is It a Ketamine-Specific Effect?. <b>2019</b> , 176, 250-251	10
303	Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial. <b>2019</b> , 96, 83-91	4
302	Safety and Effectiveness of Longer-Term Phentermine Use: Clinical Outcomes from an Electronic Health Record Cohort. <b>2019</b> , 27, 591-602	24
301	Bupropion, Alone and in Combination with Naltrexone, Blunts Binge-Like Ethanol Drinking and Intake Following Chronic Intermittent Access to Ethanol in Male C57BL/6J Mice. <b>2019</b> , 43, 783-790	11
300	Pharmacotherapy of Obesity: Limits and Perspectives. <b>2019</b> , 19, 349-364	7
299	Intranasal glucagon acutely increases energy expenditure without inducing hyperglycaemia in overweight/obese adults. <b>2019</b> , 21, 1357-1364	8
298	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY. <b>2019</b> , 25, 69-100	191
297	Evolution of Endoscopic Bariatric Devices: From Development to Practice. <b>2019</b> , 114, 679-683	3
296	Current Treatments on Obesity. <b>2019</b> , 19, 171	2
295	Activation of Kappa Opioid Receptor Regulates the Hypothermic Response to Calorie Restriction and Limits Body Weight Loss. <b>2019</b> , 29, 4291-4299.e4	13
294	A Preliminary, Open-Label Study of Naltrexone and Bupropion Combination Therapy for Treating Binge Drinking in Human Subjects. <b>2020</b> , 55, 56-62	4
293	Bariatric Endocrinology. <b>2019</b> ,	
292	Neuropeptide receptors as potential pharmacological targets for obesity. <b>2019</b> , 196, 59-78	7
291	Pharmacotherapy for Weight Management. <b>2019</b> , 395-411	1
290	Body Weight Considerations in the Management of Type 2 Diabetes. <b>2019</b> , 36, 44-58	57
289	Precision Medicine in Weight Loss and Healthy Living. <b>2019</b> , 62, 15-20	20
288	Medications Indicated for Chronic Weight Management. <b>2019</b> , 401-424	
287	Treating obesity in patients with cardiovascular disease: the pharmacotherapeutic options. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 585-593	4 9

286	Pharmacologic Agents Chapter for Abdominal Obesity. <b>2019</b> , 51-66	1
285	Pharmacotherapy of obesity: Available medications and drugs under investigation. <b>2019</b> , 92, 170-192	98
284	Obesity Management. <b>2019</b> ,	1
283	Obesity and Therapeutic Approaches to Weight Loss. <b>2019</b> , 71-85	
282	Choosing a Medication. <b>2019</b> , 105-119	
281	Important lessons about testosterone therapy- weight loss vs. testosterone therapy for symptom resolution, classical vs. functional hypogonadism, and shortterm vs. lifelong testosterone therapy. <b>2020</b> , 23, 585-591	2
280	Hypertension in Obesity: Novel Insights. <b>2020</b> , 16, 30-36	4
279	The safety and effectiveness of commonly-marketed natural supplements for weight loss in populations with obesity: A critical review of the literature from 2006 to 2016. <b>2020</b> , 60, 1614-1630	14
278	Nonalcoholic Steatohepatitis After Liver Transplantation. <b>2020</b> , 26, 141-159	16
277	Naltrexone-bupropion (Mysimba) in management of obesity: A systematic review and meta-analysis of unpublished clinical study reports. <b>2020</b> , 86, 646-667	9
276	The melanocortin system as a potential target for treating alcohol use disorders: A review of pre-clinical data. <b>2020</b> , 1730, 146628	2
275	Anorectic state of obesity medications in the United States. Are leaner times ahead?. <i>Expert Opinion on Pharmacotherapy</i> , <b>2020</b> , 21, 167-172	4 2
274	Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs. <b>2020</b> , 13, 53-64	39
273	Reprint of: Recent Updates on Obesity Treatments: Available Drugs and Future Directions. <b>2020</b> , 447, 191-215	6
272	SEEDO-SEMERGEN consensus document on continuous care of obesity between primary care and specialist Hospital units 2019. <b>2020</b> , 155, 267.e1-267.e11	0
271	Foreword. <b>2020</b> , xii-xiv	
270	Concepts of Addiction. <b>2020</b> , 1-50	
269	Appetitive Needs and Addiction. <b>2020</b> , 3-11	8



268	Behavioral Economics and Addictive Disorders. <b>2020</b> , 12-22	40
267	Sensitization of Incentive Salience and the Transition to Addiction. <b>2020</b> , 23-37	40
266	Philosophical Issues in the Addictions. <b>2020</b> , 38-50	
265	Clinical and Research Methods in the Addictions. <b>2020</b> , 51-118	
264	Human Neurobiological Approaches to Hedonically Motivated Behaviors. <b>2020</b> , 53-61	40
263	Human Laboratory Paradigms in Addictions Research. <b>2020</b> , 62-72	
262	Behavioral Economic Considerations of Novel Addictions and Nonaddictive Behavior: Research and Analytic Methods. <b>2020</b> , 73-86	40
261	Substance and Behavioral Addictions Assessment Instruments. <b>2020</b> , 87-105	1
260	Qualitative Approaches to the Study of Substance and Behavioral Addictions. <b>2020</b> , 106-118	1
259	Levels of Analysis and Etiology. <b>2020</b> , 119-198	
258	Neurobiology of Substance Addictions. <b>2020</b> , 121-135	40
257	Neurobiological Foundations of Behavioral Addictions. <b>2020</b> , 136-151	40
256	Multiple Memory Systems, Addiction, and Health Habits: New Routes for Translational Science. <b>2020</b> , 152-170	40
255	The Role of Culture in Addiction. <b>2020</b> , 171-181	2
254	The Physical and Social Environments as Determinants of Health: Implications for Substance and Behavioral Addictions. <b>2020</b> , 182-198	
253	Prevention and Treatment. <b>2020</b> , 199-294	
252	Adolescent Drug Misuse Prevention: Challenges in School-Based Programming. <b>2020</b> , 201-214	1
251	Treatment of Alcohol, Tobacco, and Other Drug (ATOD) Misuse. <b>2020</b> , 215-229	2

250	Prevention and Treatment of Food Addiction. <b>2020</b> , 230-240	40
249	The Prevention and Treatment of Gambling Disorders: Some Art, Some Science. <b>2020</b> , 241-253	42
248	Prevention and Treatment of Sex Addiction. <b>2020</b> , 254-261	1
247	Passionate Love Addiction: An Evolutionary Survival Mechanism That Can Go Terribly Wrong. <b>2020</b> , 262-270	
246	Prevention and Treatment of Compulsive Buying Disorder. <b>2020</b> , 271-279	40
245	Prevention and Treatment of Work Addiction. <b>2020</b> , 280-287	
244	Gaming Disorder and Its Treatment. <b>2020</b> , 288-294	1
243	Ongoing and Future Research Directions. <b>2020</b> , 295-425	
242	Precision Behavioral Management (PBM): A Novel Genetically Guided Therapy to Combat Reward Deficiency Syndrome (RDS) Relevant to the Opiate Crisis. <b>2020</b> , 297-306	40
241	Novel Psychoactive Substances: A New Challenge for Prevention and Treatment. <b>2020</b> , 307-325	
240	Impaired Physicians. <b>2020</b> , 326-332	
239	Feedback Models for Gambling Control: The Use and Efficacy of Online Responsible Gambling Tools. <b>2020</b> , 333-339	40
238	Food versus Eating Addictions. <b>2020</b> , 340-351	40
237	Measurement, Prevention, and Treatment of Exercise Addiction. <b>2020</b> , 352-361	
236	Tanning as an Addiction: The State of the Research and Implications for Intervention. <b>2020</b> , 362-372	40
235	Considering the Overlap and Nonoverlap of Compulsivity, Impulsivity, and Addiction. <b>2020</b> , 373-385	41
234	Anhedonia in Addictive Behaviors. <b>2020</b> , 386-408	
233	Mindfulness-Based Interventions Applied to Addiction Treatments. <b>2020</b> , 409-417	40

232	American Legal Issues in Addiction Treatment and Research. <b>2020</b> , 418-425	
231	Index. <b>2020</b> , 426-446	
230	The risk of cardiovascular complications with current obesity drugs. <b>2020</b> , 19, 1095-1104	6
229	A Review of Past and Present Weight Loss Strategies and the Potential Role of Bariatric Arterial Embolization. <b>2020</b> , 04, 195-205	
228	Obesity in adults: a clinical practice guideline. <b>2020</b> , 192, E875-E891	192
227	Mediterranean Diet and Naltrexone/Bupropion Treatment for Weight Loss in Overweight and Obese Breast Cancer Survivors and Non-Cancer Participants: A Pilot Randomized Controlled Trial. <b>2020</b> , 13, 3325-3335	2
226	Randomized Controlled Trial of Behavioral Weight Loss and Stepped Care for Binge-Eating Disorder: 12-Month Follow-up. <b>2020</b> , 28, 2116-2124	6
225	Weight loss: Lifestyle interventions and pharmacotherapy. <b>2020</b> , 219-234	
224	Testosterone Therapy for Prevention and Treatment of Obesity in Men. <b>2020</b> , 1, 40-61	2
223	Therapeutic potential of $\alpha$ 7 nicotinic acetylcholine receptor agonists to combat obesity, diabetes, and inflammation. <b>2020</b> , 21, 431-447	7
222	SEEDO-SEMERGEN consensus document on continuous care of obesity between Primary Care and Specialist Hospital Units 2019. <b>2020</b> , 155, 267.e1-267.e11	4
221	Recent Updates on Obesity Treatments: Available Drugs and Future Directions. <b>2020</b> , 437, 215-239	23
220	Weight-centric pharmacological management of type 2 diabetes mellitus - An essential component of cardiovascular disease prevention. <b>2020</b> , 34, 107619	7
219	Obesity Treatment: A Focus on Pharmacotherapy of Weight Management. <b>2020</b> , 39, 121-127	1
218	Medications Available for Weight Reduction in Elective Total Joint Arthroplasty. <b>2020</b> , 8, e0123	0
217	Medications for the treatment of obesity in adolescents. <b>2020</b> , 11, 2042018820918789	11
216	Pharmacological therapies to address obesity in type 1 diabetes. <b>2020</b> , 27, 194-206	3
215	Cardiometabolic Disease and Dysfunction Following Spinal Cord Injury: Origins and Guideline-Based Countermeasures. <b>2020</b> , 31, 415-436	11

214	A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome. <b>2020</b> , 11, 2042018820938305	24
213	Reproductive Consequences of Obesity. <b>2020</b> ,	1
212	Modern pharmacological treatment of obese patients. <b>2020</b> , 11, 2042018819897527	28
211	Legend of Weight Loss: a Crosstalk Between the Bariatric Surgery and the Brain. <b>2020</b> , 30, 1988-2002	16
210	Cardiovascular Risks and Benefits of Medications Used for Weight Loss. <b>2019</b> , 10, 883	6
209	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM -. <b>2020</b> , 26, 107-139	206
208	The limits and challenges of antiobesity pharmacotherapy. <i>Expert Opinion on Pharmacotherapy</i> , <b>2020</b> , 21, 1319-1328	4 9
207	An open-label trial on the efficacy and tolerability of naltrexone/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder. <b>2021</b> , 26, 779-788	12
206	Effects of bariatric surgery on lipid-lipoprotein profile. <b>2021</b> , 115, 154441	2
205	Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging. <b>2021</b> , 18, 291-304	33
204	Best Practices in the Management of Overweight and Obesity. <b>2021</b> , 105, 149-174	18
203	The Neurobiology of Binge-eating Disorder Compared with Obesity: Implications for Differential Therapeutics. <b>2021</b> , 43, 50-69	8
202	Weight-loss response to naltrexone/bupropion is modulated by the Taq1A genetic variant near DRD2 (rs1800497): A pilot study. <b>2021</b> , 23, 850-853	3
201	Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study. <b>2021</b> , 43, 112-122.e1	7
200	Extended-release naltrexone/bupropion and liver health: Pooled, post hoc analysis from four randomized controlled trials. <b>2021</b> , 23, 861-865	5
199	Clinical Impact of Weight-Loss Pharmacotherapy in Patients with Atherosclerotic Cardiovascular Disease. <b>2021</b> , 21, 271-281	3
198	Cardiovascular outcome trials in obesity: A review. <b>2021</b> , 22, e13112	12
197	Treatment-Related Evidence that Food Addiction Is a Valid Construct. <b>2021</b> , 143-151	

196	Pathophysiology of Obesity and Cancer: Drugs and Signaling Targets. <b>2021</b> , 43-63		
195	Pharmacologie de l'obésité vers de nouvelles options. <b>2021</b> , 663-672		
194	Economic value of nonsurgical weight loss in adults with obesity. <b>2021</b> , 27, 37-50		4
193	Obesity: Medical and Surgical Treatment. <b>2021</b> , 131-175		
192	Long-term effects of weight-reducing drugs in people with hypertension. <b>2021</b> , 1, CD007654		2
191	Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review. <b>2021</b> , 39, 208-221		21
190	Medikamentöse Therapie der Adipositas. <b>2021</b> , 16, 16-21		
189	Binge-Eating Disorder and Type 2 Diabetes: A Review. <b>2021</b> , 27, 158-164		4
188	Long-Term Weight Loss Strategies for Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, 1854-1866	5.6	5
187	Abnehmen mit Arzneimitteln? Pharmakotherapie von Übergewicht und Adipositas. <b>2021</b> , 46, 41-55		
186	An update on pharmacotherapeutic strategies for obesity. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 1305-1318	4	3
185	Sex Differences in Alcohol Consumption and Alcohol-Associated Liver Disease. <b>2021</b> , 96, 1006-1016		4
184	Aversion to Off-label Prescribing in Clinical Pediatric Weight Management: The Quintessential Double Standard. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, 2103-2113	5.6	1
183	Cardiovascular safety of naltrexone and bupropion therapy: Systematic review and meta-analyses. <b>2021</b> , 22, e13224		0
182	Obesity Primer for the Practicing Gastroenterologist. <b>2021</b> , 116, 918-934		2
181	Pharmacologically induced weight loss is associated with distinct gut microbiome changes in obese rats.		
180	Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide-1 Receptor Agonists. <b>2021</b> , 38, 2821-2839		10
179	Cardiovascular safety of long-term anti-obesity drugs in subjects with overweight or obesity: a systematic review and meta-analysis. <b>2021</b> , 77, 1611-1621		2

178	In search of an ideal drug for safer treatment of obesity: The false promise of pseudoephedrine. <b>2021</b> , 1	0
177	Mesolimbic opioid-dopamine interaction is disrupted in obesity but recovered by weight loss following bariatric surgery. <b>2021</b> , 11, 259	0
176	Evaluation of Pharmacologic Interventions for Weight Management in a Veteran Population. <b>2021</b> , 38, 220-226	
175	Psychiatric Safety and Weight Loss Efficacy of Naltrexone/bupropion as Add-on to Antidepressant Therapy in Patients with Obesity or Overweight. <b>2021</b> , 289, 167-176	0
174	Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial. <b>2021</b> , 45, 1687-1695	1
173	Obesity in Patients with Type 1 Diabetes: Links, Risks and Management Challenges. <b>2021</b> , 14, 2807-2827	5
172	Pharmacotherapy in Childhood Obesity. <b>2021</b> ,	0
171	Obstetrician-Gynecologists' Strategies for Patient Initiation and Maintenance of Antiobesity Treatment with Glucagon-Like Peptide-1 Receptor Agonists. <b>2021</b> , 30, 1016-1027	1
170	Management of Obesity and Nonalcoholic Fatty Liver Disease: A Literature Review. <b>2021</b> , 41, 435-447	1
169	Pharmacotherapy of obesity: An update. <b>2021</b> , 169, 105649	7
168	Safety and efficacy of naltrexone for weight loss in adult patients - a systematic review. <b>2021</b> , 17, 940-953	
167	Diets and drugs for weight loss and health in obesity - An update. <b>2021</b> , 140, 111789	11
166	Identification of the thistle milk component Silibinin(A) and Glutathione-disulphide as potential inhibitors of the pancreatic lipase: Potential implications on weight loss. <b>2021</b> , 83, 104479	0
165	Effects of weight loss medications on mortality and cardiovascular events: A systematic review of randomized controlled trials in adults with overweight and obesity. <b>2021</b> , 31, 2587-2595	0
164	Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases. <b>2021</b> , 13,	5
163	Obesity Management in Cardiometabolic Disease: State of the Art. <b>2021</b> , 23, 59	3
162	Gut microbiota: a target for intervention in obesity. <b>2021</b> , 15, 1169-1179	1
161	New Incretin Combination Treatments under Investigation in Obesity and Metabolism: A Systematic Review. <b>2021</b> , 14,	3

160	Developmental Considerations for the Use of Naltrexone in Children and Adolescents. <b>2021</b> , 26, 675-695	0
159	[Obesity treatment-legal and illegal drugs and the future]. <b>2021</b> , 62, 1354-1359	1
158	Obesity-An Update on the Basic Pathophysiology and Review of Recent Therapeutic Advances. <b>2021</b> , 11,	1
157	Management of Cardiometabolic Complications in Patients With Nonalcoholic Fatty Liver Disease: A Review of the Literature With Recommendations. <b>2021</b> , 55, 747-756	1
156	Lateral hypothalamus-projecting noradrenergic locus coeruleus pathway modulates binge-like ethanol drinking in male and female TH-ires-cre mice. <b>2021</b> , 196, 108702	3
155	Additional considerations in gynecologic care. <b>2022</b> , 148-187.e6	
154	Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?. <b>2021</b> , 10, 14-30	31
153	Psychological Co-morbidities of Obesity. <b>2011</b> , 1-72	4
152	Obesity therapy. <b>2020</b> , 38, 9-18	5
151	Surgical and Nonsurgical Weight Loss for Patients with Obstructive Sleep Apnea. <b>2020</b> , 53, 409-420	3
150	[Pharmacological treatment of obesity for Primary Care physicians]. <b>2019</b> , 45, 559-565	1
149	Combining obesity pharmacotherapy with endoscopic bariatric and metabolic therapies. <b>2020</b> , 22, 154-158	2
148	The Cambridge Handbook of Substance and Behavioral Addictions. <b>2020</b> ,	44
147	Randomized controlled trial testing the effectiveness of adaptive "SMART" stepped-care treatment for adults with binge-eating disorder comorbid with obesity. <b>2020</b> , 75, 204-218	17
146	The association between weight-promoting medication use and weight gain in postmenopausal women: findings from the Women's Health Initiative. <b>2020</b> , 27, 1117-1125	3
145	Treatment of Obesity in Mitigating Metabolic Risk. <b>2020</b> , 126, 1646-1665	18
144	CNS-targeting pharmacological interventions for the metabolic syndrome. <b>2019</b> , 129, 4058-4071	13
143	Identification and Management of Cardiometabolic Risk after Spinal Cord Injury: Clinical Practice Guideline for Health Care Providers. <b>2018</b> , 24, 379-423	41

142	. <b>2020</b> , 192, E1757-E1775	1
141	Lifestyle modification in the management of the metabolic syndrome: achievements and challenges. <b>2010</b> , 3, 373-85	38
140	Obesity Therapy: How and Why?. <b>2020</b> , 27, 174-186	16
139	Current Options for the Pharmacotherapy of Obesity. <b>2019</b> , 25, 2019-2032	2
138	Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy. <b>2020</b> , 20, 1232-1243	5
137	New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists. <b>2020</b> , 45, 127-137	12
136	Pharmacological Treatment of Obesity. <b>2011</b> , 41, 489-495	4
135	Therapies for obesity and medication-associated weight gain. <b>2013</b> , 51, 13-6	5
134	Naltrexone/Bupropion combination therapy in overweight or obese patients with major depressive disorder: results of a pilot study. <b>2013</b> , 15,	17
133	Comprehensive Review of Current and Upcoming Anti-Obesity Drugs. <b>2020</b> , 44, 802-818	17
132	Treating morbid obesity in cirrhosis: A quest of holy grail. <b>2015</b> , 7, 2819-28	14
131	The Role of Anti-Obesity Medication in Prevention of Diabetes and Its Complications. <b>2019</b> , 28, 158-166	11
130	Current Long-Term Pharmacotherapies for the Management of Obesity. <b>2020</b> , 29, 99-109	3
129	Pharmacological Management of Obesity in Patients with Type 2 Diabetes: An Update. <b>2016</b> , 25, 121-128	2
128	The best drug supplement for obesity treatment: a systematic review and network meta-analysis. <b>2021</b> , 13, 110	3
127	Under-recognition of sleep-disordered breathing and other common health conditions in the West Virginia Medicaid population: a driver of poor health outcomes. <b>2021</b> ,	1
126	Novel Non-invasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy. <b>2021</b> ,	4
125	Treating the Chronic Disease of Obesity. <b>2021</b> , 105, 983-1016	1



124	Drug Therapy for Obesity. <b>2012</b> , 21, 197	10
123	Emotional Aspects of Gynecology. <b>2013</b> , 137-171	
122	Current Management of Obesity in an Infertile Female-Recent Advances and Future Prospective Drugs.	0
121	Medical Management of Obesity. <b>2014</b> , 503-520	
120	Drugs for Weight Loss and Maintenance: Present and Future. <b>2014</b> , 225-245	
119	THE EFFECT OF SEPTAL LESION ON NALOXONE INDUCED HYPOPHAGIA IN RATS. <b>2014</b> , 3, 1625-1632	
118	Prescription Medications for the Treatment of Obesity. <b>2015</b> , 261-270	
117	Medikamentöse Therapie der Adipositas. <b>2015</b> , 535-542	
116	The Doctor's Tool Kit: Pharmacotherapy for the Patient with Obesity. <b>2015</b> , 91-109	
115	Pharmacotherapy of Obesity and Metabolic Syndrome. <b>2015</b> , 1-16	
114	Safety of Anti-Obesity Drugs Approved for Long-Term Use. <b>2015</b> , 24, 17-27	6
113	Diagnosing Bulimia Nervosa. 105-113	
112	New Drugs for Obesity Treatment. <b>2016</b> , 90, 121-126	1
111	Individualizing Lifestyle Therapy for Patients with Obesity. <b>2016</b> , 22, 14-20	
110	Addictive Disorders in Severe Obesity and After Bariatric Surgery. <b>2017</b> , 141-156	1
109	Medications Indicated for Chronic Weight Management. <b>2017</b> , 1-24	
108	Weight Loss Medication in Bariatric Surgery. <b>2017</b> , 6, 1-5	
107	Role of Pharmacotherapy in the Treatment of Pediatric Obesity and Its Comorbidities. <b>2018</b> , 613-627	1

106	Les traitements médicamenteux de l'obésité <b>2017</b> , 47, 304-309	1
105	Recent Advances in Anti-Obesity Agents. <b>2018</b> , 93, 501-508	7
104	Neue Arzneimittel 2018. <b>2019</b> , 61-175	1
103	Preface. <b>2020</b> , xv-xvii	
102	Obesity. <b>2020</b> , 1903-1913	
101	Mesolimbic opioid-dopamine interaction is disrupted in obesity but recovered by weight loss following bariatric surgery.	
100	Therapeutic Management of Obesity. <b>2021</b> , 323-339	1
99	Nutrition and blood pressure. <b>2022</b> , 699-739	
98	Childhood obesity: A review of current and future management options. <b>2021</b> ,	2
97	Drugs for Weight Loss and Maintenance: Present and Future. <b>2014</b> , 225-245	0
96	Pharmacotherapy in pediatric obesity: current evidence and landscape. <b>2021</b> , 28, 55-63	4
95	Naltrexone SR/Bupropion SR (Contrave): A New Approach to Weight Loss in Obese Adults. <b>2011</b> , 36, 255-62	19
94	Treatment options for obesity and potential therapies on the horizon. <b>2011</b> , 36, 282-301	1
93	Naltrexone/Bupropion ER (Contrave): Newly Approved Treatment Option for Chronic Weight Management in Obese Adults. <b>2016</b> , 41, 164-72	16
92	Gender-related Differences in Food Craving and Obesity. <b>2016</b> , 89, 161-73	56
91	Obesity Management: Clinical Review and Update of the Pharmacologic Treatment Options. <b>2016</b> , 33, 6-16	1
90	Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience. <b>2021</b> ,	3
89	Liraglutide for Weight Management in the Real World: Significant Weight Loss Even if the Maximal Daily Dose Is Not Achieved. <b>2021</b> , 1-7	3

88	Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. <i>Lancet, The</i> , <b>2021</b> ,	4.0	13
87	Anti-obesity drug discovery: advances and challenges. <b>2021</b> ,		4.0
86	Obesity in cystic fibrosis. <b>2021</b> , 26, 100276		1
85	Obesity; Its Prevalence, Consequences and Potential Therapies. <b>2021</b> , 233-248		
84	Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis.. <b>2022</b> , 75, 718		0
83	Drugs for Treating Obesity. <b>2021</b> ,		3
82	Medical Management of Obesity as it Affects Reflux. 263451612110691		
81	Highlights of mechanisms and treatment of obesity-related hypertension.. <i>Journal of Human Hypertension</i> , <b>2022</b> ,	2.6	2
80	New Horizons A New Paradigm for Treating to Target with Second-Generation Obesity Medications. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> ,	5.6	5
79	Obesogenic Medications and Weight Gain Over 24 Weeks in Patients with Depression: Results from the GUIDED Study. <i>Psychopharmacology Bulletin</i> , <b>2021</b> , 51, 8-30	0.9	
78	Pharmacological Treatment of Obesity. <b>2022</b> , 435-442		
77	Treatment of Obesity in the Patient with Type 2 Diabetes. <b>2022</b> , 451-459		
76	Obesity and Diabetes. <b>2022</b> , 1-61		
75	Novel Approaches to Tackling Emotional Loss of Control of Eating Across the Weight Spectrum.. <i>Proceedings of the Nutrition Society</i> , <b>2022</b> , 1-25	2.9	0
74	Adjunctive Therapy, Including Pharmacotherapy. <b>2022</b> , 279-296		
73	Pharmacologically induced weight loss is associated with distinct gut microbiome changes in obese rats.. <i>BMC Microbiology</i> , <b>2022</b> , 22, 91	4.5	1
72	A contemporary view on obesity treatment in adults. <i>Reproductive Endocrinology</i> , <b>2021</b> , 45-50	0.2	2
71	Pharmacotherapy of obesity in complex diseases. <i>Clinical Obesity</i> , <b>2021</b> , e12497	3.6	1

70	Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. <b>2022</b> , 100018		1
69	Clinical Evaluation, Lifestyle, and Pharmacological Management of Obesity. <b>2022</b> , 221-240		
68	Terapia farmacologica dell'obesità: attualità e prospettive future. <i>L'Endocrinologo</i> ,	0	
67	The relationship between early weight loss and weight loss maintenance with naltrexone-bupropion therapy. <i>EClinicalMedicine</i> , <b>2022</b> , 49, 101436	11.3	1
66	Pharmacological Management of Obesity: A Century of Expert Opinions in Cecil Textbook of Medicine. <i>American Journal of Therapeutics</i> , Publish Ahead of Print,	1	
65	Weight-centric treatment of depression and chronic pain. <b>2022</b> , 100025		0
64	Medical Weight Management: A Multidisciplinary Approach.		
63	Recent Advances in Anti-Obesity Drugs. <i>Journal of Korean Diabetes</i> , <b>2022</b> , 23, 113-127	0.1	1
62	Biomaterial-Based Therapeutic Strategies for Obesity and Its Comorbidities. <i>Pharmaceutics</i> , <b>2022</b> , 14, 1445	6.4	1
61	A narrative review of anti-obesity medications for obese patients with osteoarthritis. <i>Expert Opinion on Pharmacotherapy</i> , 1-15	4	0
60	Anti-obesity weight loss medications: Short-term and long-term use. <i>Life Sciences</i> , <b>2022</b> , 306, 120825	6.8	1
59	Polypharmacology in Clinical Applications: Metabolic Disease Polypharmacology. <b>2022</b> , 199-229		
58	Medikamentöse Therapie der Adipositas. <b>2022</b> , 603-609		
57	Pharmacologic treatment of obesity. <b>2022</b> , 65, 408-416		
56	Pharmacotherapy in obesity: the current state and the near future. <b>2022</b> , 65, 514-531		
55	Pharmacologic Weight Management in the Era of Adolescent Obesity.		0
54	WITHDRAWN: American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan 2022 Update. <b>2022</b> ,		8
53	Medical and Surgical Treatment of Obesity. <b>2022</b> ,		

52	Effects of solriamfetol treatment on body weight in participants with obstructive sleep apnea or narcolepsy. <b>2022</b> , 100, 165-173	0
51	Medical Management of Obesity. <b>2021</b> , 1-19	0
50	Decision-making in the management of obesity: a scoping review protocol. Publish Ahead of Print,	0
49	The Australian Obesity Management Algorithm: A simple tool to guide the management of obesity in primary care. <b>2022</b> ,	4
48	Signaling pathways in obesity: mechanisms and therapeutic interventions. <b>2022</b> , 7,	4
47	Is there a therapeutic potential in combining bupropion and naltrexone in schizophrenia?. 1-13	0
46	Which is the optimal antiobesity agent for patients with nonalcoholic fatty liver disease?. 13,	0
45	Targeting Nanotechnology and Nutraceuticals in Obesity: An Updated Approach. <b>2022</b> , 28,	0
44	Efficacy and safety of traditional chinese medicine treatment for overweight and obese individuals: A systematic review and meta-analysis. 13,	0
43	Medical treatment of weight loss in children and adolescents with obesity. <b>2022</b> , 185, 106471	2
42	Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial.	1
41	Weight loss between glucagon-like peptide-1 receptor agonists and bariatric surgery in adults with obesity: A systematic review and meta-analysis. <b>2022</b> , 30, 2111-2121	1
40	AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. <b>2022</b> , 163, 1198-1225	1
39	Non-Surgical Management of Obesity. <b>2022</b> , 33-45	0
38	New therapies for obesity.	2
37	A comparison between weight loss outcomes with anti-obesity medications before and during Covid-19 pandemic at a tertiary weight management center. <b>2022</b> , 4, 100046	0
36	Indikationsstellung in der Adipositas therapie [Surgeons first? // Indications in obesity therapy - surgeons first?. <b>2022</b> , 147, 525-538	0
35	Semaglutide 2.4 Mg for the Management of Overweight and Obesity: Systematic Literature Review and Meta-Analysis. Volume 15, 3961-3987	0

34	Pharmacologic management of weight regain following bariatric surgery. 13,	0
33	Diabetes mellitus. <b>2022</b> , 221-287	0
32	An Updated Approach to Antiobesity Pharmacotherapy: Moving Beyond the 5% Weight Loss Goal. <b>2023</b> , 7,	0
31	Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States. <b>2022</b> , 28, 740-752	2
30	Economic outcomes of antiobesity medication use among adults in the United States: A retrospective cohort study. <b>2022</b> , 28, 1066-1079	0
29	Management of Obesity and Obesity-Related Disorders: From Stem Cells and Epigenetics to Its Treatment. <b>2023</b> , 24, 2310	0
28	Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5.	0
27	The Impact of Various Methods of Obesity Treatment on the Quality of Life and Mental Health Narrative Review. <b>2023</b> , 20, 2122	0
26	The Relative Value of Anti-Obesity Medications Compared to Similar Therapies. Volume 15, 51-62	0
25	Medical Management of Obesity. <b>2023</b> , 63-81	0
24	Current and emerging medications for the management of obesity in adults. <b>2023</b> , 218, 276-283	0
23	Weight Loss for Obstructive Sleep Apnea: Pharmacological and Surgical Management. <b>2023</b> , 30, 1-5	0
22	Contemporary medical, device, and surgical therapies for obesity in adults. <b>2023</b> , 401, 1116-1130	1
21	Long-acting opioids and cardiovascular diseases: Help or hindrance!. <b>2023</b> , 149, 107144	0
20	Obesity and Aging. <b>2023</b> , 52, 317-339	0
19	Excess body weight: Novel insights into its roles in obesity comorbidities. <b>2023</b> , 92, 16-27	0
18	Pharmacological Support for the Treatment of Obesity Present and Future. <b>2023</b> , 11, 433	1
17	Obesity Pharmacotherapy: a Review of Current Practices and Future Directions. <b>2023</b> , 21, 27-47	0

16	Insights on Dietary Polyphenols as Agents against Metabolic Disorders: Obesity as a Target Disease. <b>2023</b> , 12, 416	1
15	Successful naltrexone-bupropion treatment after several treatment failures in a patient with severe monogenic obesity. <b>2023</b> , 26, 106199	0
14	Five-year Weight Loss Maintenance With Obesity Pharmacotherapy.	0
13	The Case for Bariatric Surgery in Patients with Class 1 Obesity.	0
12	Current treatment landscape for obesity in Singapore. <b>2023</b> , 64, 172	0
11	Pharmacological approaches to the prevention of type 2 diabetes mellitus. 14,	0
10	Obesity and cardiovascular disease: An executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC). 10,	0
9	Medikamentöse Therapie der Adipositas – Konkurrenz zur bariatrischen Chirurgie oder sinnvolle Ergänzung?.	0
8	Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. <b>2023</b> , 58, 101882	0
7	Obesity and Cardiovascular Risk: Systematic Intervention Is the Key for Prevention. <b>2023</b> , 11, 902	1
6	Evaluation and Treatment of Obesity and Its Comorbidities: 2022 Update of Clinical Practice Guidelines for Obesity by the Korean Society for the Study of Obesity. <b>2023</b> , 32, 1-24	0
5	Cost-effectiveness analysis of five anti-obesity medications from a US payer's perspective. <b>2023</b> ,	0
4	Obesity in Adults: Position Statement of Polish Association for the Study on Obesity, Polish Association of Endocrinology, Polish Association of Cardiometabolism, Polish Psychiatric Association, Section of Metabolic and Bariatric Surgery of the Association of Polish Surgeons, and the College of Family Physicians in Poland. <b>2023</b> , 15, 1641	0
3	Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options. <b>2023</b> , 28, 3094	0
2	Pharmacologic management for polycystic ovary syndrome: Weight loss. <b>2024</b> , 122-129	0
1	Medications for obesity management: Effectiveness and value. <b>2023</b> , 29, 569-575	0